To date, no clinical (human) trials have been conducted regarding neuron stem cells (NSCs) in the treatment of MS, but a preclinical study using animal models showed that transplanted NSCs can differentiate into (become) neurons, integrate damaged tissues, and improve the mobility of sick mice.

The transplanted cells not only repaired the damaged tissues, but also dramatically decreased T-cell infiltration in the treated mice.

Although these preclinical results may be controversial, early NSC mortality after transplant and neural cell response may be responsible for beneficial effects following cell transplant. Additionally, NSCs have a low immunogenic potential for activating peripheral lymphocytes (natural killer cells, T-cells and B-cells).

Still, more pre-clinical studies are necessary before NSCs therapies are tested in a clinical setting.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

____________________

  1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817403/
  2. http://link.springer.com/article/10.1007%2Fs11427-016-0114-9

Promising Phase 1 Trial Results of Stem Cell Therapy in Progressive MS Patients Being Presented at AAN Meeting

Potentially groundbreaking research by the Tisch Multiple Sclerosis Research Center of New York (MSRCNY) will be presented on April 19 at the 68th American Academy of Neurology (AAN) Annual Meeting taking place in Vancouver, Canada. Dr. Saud A. Sadiq, director and chief research scientist at the Tisch center, will present results of a Phase 1 clinical trial of a […]

Preliminary Results For MS Stem Cell Trial Reveals Safety, Tolerability in Test Subjects

Tisch MS Research Center of New York (Tisch MSRCNY) researchers presented preliminary results from an FDA-approved Phase I trial, a small-scale investigation in humans using autologous neural stem cells for the treatment of multiple sclerosis (MS). MS is an autoimmune disorder in which the body’s immune system launches an attack against myelin, the fatty substance that […]